Remembering Mr. Les Goldman
Northwest Biotherapeutics, known for its groundbreaking work in developing personalized immune therapies for solid tumors, is mourning the loss of its Senior Vice President and General Counsel, Mr. Les Goldman. He passed away due to a stroke, leaving an indelible mark on the company and the many lives he touched through his passionate work.
A Legacy of Dedication
Mr. Goldman was not just a key executive; he was a pivotal figure in advancing the mission of Northwest Biotherapeutics. His tireless dedication to the company’s vision and his commitment to serving cancer patients were evident in all of his endeavors. The management team has taken on his responsibilities to ensure continuity and maintain the high standards Mr. Goldman exemplified throughout his career.
About Northwest Biotherapeutics
Northwest Biotherapeutics focuses on developing innovative immunotherapy products aimed at treating cancer effectively while minimizing the toxic side effects commonly associated with standard chemotherapy. The company is renowned for its DCVax® dendritic cell-based vaccines, which harness the body’s immune system to target and eliminate cancer cells. Among its notable projects, the DCVax®-L treatment for glioblastoma stands out. Glioblastoma is recognized as one of the most aggressive types of brain cancer. The company has successfully completed a significant clinical trial with 331 patients and is awaiting regulatory approval in the UK for further commercial development.
The Future of DCVax® Therapies
Beyond glioblastoma, Northwest Biotherapeutics is also developing DCVax®-Direct, targeted for inoperable solid tumors. Following promising results from a Phase I trial involving 40 patients, the company is eager to advance to Phase II trials in the near future. These innovative treatments underscore the company’s commitment to exploring cutting-edge therapeutic options designed to improve patient outcomes.
Commitment to Cancer Research
As the world faces an increasing incidence of various cancers, the work done by Northwest Biotherapeutics, including programs in collaboration with prestigious institutions like the University of Pennsylvania, remains critically important. Together, they have explored the efficacy of DCVax®-L in advanced ovarian cancer, demonstrating the potential of personalized immunotherapy.
Contact Information
For those seeking further information about Northwest Biotherapeutics and its range of groundbreaking therapies, please reach out to:
Northwest Biotherapeutics
Dave Innes
Phone: 804-513-6758
Frequently Asked Questions
Who was Mr. Les Goldman?
Mr. Les Goldman was the Senior Vice President and General Counsel of Northwest Biotherapeutics, known for his dedication to cancer research and patient advocacy.
What was the contribution of Mr. Goldman to the company?
He played a pivotal role in advancing the company's mission and ensuring the development of innovative cancer therapies.
What is DCVax®?
DCVax® refers to a platform of dendritic cell-based vaccines developed by Northwest Biotherapeutics to target and treat various types of cancers.
What is the status of the DCVax®-L clinical trials?
The DCVax®-L treatment for glioblastoma has successfully completed a Phase III trial and awaits regulatory review for commercial approval.
How can I learn more about Northwest Biotherapeutics?
You can contact them via phone for more information on their innovative therapies and research initiatives.
